Compass Therapeutics Sees Unusually High Options Volume (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of unusually large options trading on Tuesday. Traders purchased 7,069 call options on the company. This represents an increase of approximately 411% compared to the average daily volume of 1,383 call options.

Analysts Set New Price Targets

CMPX has been the topic of a number of research reports. Guggenheim restated a “buy” rating and set a $12.00 target price on shares of Compass Therapeutics in a report on Tuesday, March 24th. William Blair reiterated an “outperform” rating on shares of Compass Therapeutics in a research note on Thursday, March 5th. D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a research note on Thursday, March 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.20.

Institutional Trading of Compass Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new position in Compass Therapeutics in the fourth quarter worth about $132,000. Seven Fleet Capital Management LP purchased a new stake in shares of Compass Therapeutics during the fourth quarter valued at approximately $3,054,000. Invesco Ltd. increased its position in shares of Compass Therapeutics by 5.3% during the fourth quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock valued at $343,000 after acquiring an additional 3,245 shares in the last quarter. XTX Topco Ltd increased its position in shares of Compass Therapeutics by 582.2% during the fourth quarter. XTX Topco Ltd now owns 115,634 shares of the company’s stock valued at $621,000 after acquiring an additional 98,684 shares in the last quarter. Finally, Ikarian Capital LLC purchased a new position in Compass Therapeutics in the 4th quarter worth approximately $4,296,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Trading Up 2.6%

Compass Therapeutics stock opened at $5.43 on Thursday. The business’s fifty day simple moving average is $5.86 and its two-hundred day simple moving average is $5.06. Compass Therapeutics has a 12 month low of $1.40 and a 12 month high of $6.88. The company has a market capitalization of $977.89 million, a price-to-earnings ratio of -12.63 and a beta of 1.49.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. On average, equities research analysts predict that Compass Therapeutics will post -0.36 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.